



2021-2022 General Assembly

HOUSE BILL 103: 2022 Appropriations Act, Sec. 9F.2: Prescription Digital Therapeutics Pilot Program for Opioid Use Disorder Treatment

| | | | |
|-----------------------|---------------------------|---------------------|---------------------------------|
| Committee: | | Date: | August 3, 2022 |
| Introduced by: | | Prepared by: | Jessica Boney Staff Attorney |
| Analysis of: | Sec. 9F.2 of S.L. 2022-74 | | |

OVERVIEW: *Section 9F.2.(a) of S.L. 2022-74 authorizes the Department of Health and Human Services, Division of Mental Health, Developmental Disabilities, and Substance Abuse Services (DMH/DD/SAS) to develop and administer, from the funds allocated in Section 9F.1 of this act, a two-year pilot program to gauge the effectiveness of prescription digital therapeutics (PDTs) for the treatment of opioid use disorder administer*

Section 9F.2.(b) of S.L. 2022-74 directs the pilot program to commence no later than December 1, 2022, and terminate no later than December 1, 2024. DMH/DD/SAS is responsible for determining the number of pilot program sites, the eligibility requirements for participants, and the specific types of PDTs that will be prescribed and evaluated by the pilot program.

Section 9F.2.(c) of S.L. 2022-74 instructs DMH/DD/SAS to submit a report on the impact of the pilot program to the Joint Legislative Oversight Committee on Health and Human Services within six months after the termination of the pilot program. The report must include specified criteria, including a breakdown of expenditures, and identification of the specific PDTs prescribed and an evaluation of their effectiveness.

This section became effective July 1, 2022.

Jeffrey Hudson
Director



Legislative Analysis
Division
919-733-2578